Dr James Watson
Contact information
Podcast interview

Primaquine is a drug used to eliminate vivax malaria from the liver and prevent relapses. However, it causes anaemia in patients with G6PD deficiency. A new, slightly longer regimen with increasing doses of primaquine could allow to safely treat all patients with vivax malaria.
Research groups
James Watson
Senior Scientist
Clinical Therapeutics
I am broadly interested in applied and theoretical statistics, causal inference, applied genetics and pharmacology. I am a believer in Bayes but will go with whatever works best. Most of my work has been related to falciparum and vivax malaria. I have a particular interest in G6PD deficiency: how to model haemolysis in G6PD deficient individuals and understanding the selection mechanisms that have led to high prevalences of G6PD deficiency across the malaria endemic world.
Causal pathways in severe malaria
Recent publications
-
Improving statistical power in severe malaria genetic association studies by augmenting phenotypic precision.
Journal article
Watson JA. et al, (2021), eLife, 10
-
Definitions matter: heterogeneity of COVID-19 disease severity criteria and incomplete reporting compromise meta-analysis
Journal article
Guerin PJ. et al, (2021)
-
Improving statistical power in severe malaria genetic association studies by augmenting phenotypic precision
Journal article
Watson JA. et al, (2021)
-
The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions
Journal article
Schilling WHK. et al, (2021), Wellcome Open Research, 6, 71 - 71
-
Protective effect of Mediterranean-type glucose-6-phosphate dehydrogenase deficiency against Plasmodium vivax malaria
Journal article
Awab GR. et al, (2021), eLife, 10